JNJ-73763989の市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

JNJ-3989（旧ARO-HBV）は、第3世代の皮下投与型RNAi治療薬候補であり、慢性HBV感染患者に対する治療薬として、Arrowhead PharmaceuticalsとJanssen Pharmaceuticalsの共同開発により開発されました。ARO-HBVは、肝細胞へのデリバリーに向けN-アセチルガラクトサミンに直接結合した2つのsiRNAを含んでいます。ARO-HBVは、共有結合で閉じた環状DNA（cccDNA）と宿主に組み込まれたウイルスDNAから形成されるすべてのmRNAをサイレンシングします。ARO-HBVは皮下投与されるため、吸収に関連した薬物相互作用（DDI）は起こりません。

JNJ-56136379（JNJ-6379）はJanssen Sciencesが開発中のCAM（Capsid Assembly Modulator）です。JNJ-66136379（JNJ-6379）はカプシドのアセンブリーを阻害し、新規感染時に共有結合で閉じた環状DNA（cccDNA）の形成を阻害するという二重の作用機序で作用します。この薬剤はHBVコアタンパク質に結合し、HBVのライフサイクルの初期と後期段階の両方のプロセスを阻害します。単剤療法での本薬は、フェーズIIでウイルスブレイクスルーが見られたため、今後の開発が中止されました。

当レポートでは、主要6市場（米国・ドイツ・フランス・イタリア・スペイン・英国）におけるB型慢性肝炎向けJNJ-73763989について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 B型慢性肝炎におけるJNJ-73763989の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 JNJ-73763989市場の評価

• B型慢性肝炎におけるJNJ-73763989の市場見通し
• 主要6市場の分析
  • 主要6市場のB型慢性肝炎向けJNJ-73763989の市場規模
• 市場の分析：国別
  • 米国のB型慢性肝炎向けJNJ-73763989の市場規模
  • ドイツのB型慢性肝炎向けJNJ-73763989の市場規模
  • 英国のB型慢性肝炎向けJNJ-73763989の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: JNJ-73763989, Clinical Trial Description, 2023
• Table 2: JNJ-73763989, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: JNJ-73763989 Market Size in the 6MM, in USD million (2019-2032)
• Table 6: JNJ-73763989 Market Size in the US, in USD million (2019-2032)
• Table 7: JNJ-73763989 Market Size in Germany, in USD million (2019-2032)
• Table 8: JNJ-73763989 Market Size in France, in USD million (2019-2032)
• Table 9: JNJ-73763989 Market Size in Italy, in USD million (2019-2032)
• Table 10: JNJ-73763989 Market Size in Spain, in USD million (2019-2032)
• Table 11: JNJ-73763989 Market Size in the UK, in USD million (2019-2032)

List of Figures

• Figure 1: JNJ-73763989 Market Size in the 6MM, USD million (2019-2032)
• Figure 2: JNJ-73763989 Market Size in the United States, USD million (2019-2032)
• Figure 3: JNJ-73763989 Market Size in Germany, USD million (2019-2032)
• Figure 4: JNJ-73763989 Market Size in France, USD million (2019-2032)
• Figure 5: JNJ-73763989 Market Size in Italy, USD million (2019-2032)
• Figure 6: JNJ-73763989 Market Size in Spain, USD million (2019-2032)
• Figure 7: JNJ-73763989 Market Size in the United Kingdom, USD million (2019-2032)

"JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JNJ-73763989 for chronic hepatitis B in the six major markets. A detailed picture of the JNJ-73763989 for chronic hepatitis B in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the JNJ-73763989 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JNJ-73763989 market forecast analysis for chronic hepatitis B in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary:

JNJ-3989, formerly ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate, was developed as a potential treatment for patients with chronic HBV infection in collaboration with Arrowhead Pharmaceuticals and Janssen Pharmaceuticals. ARO-HBV contains two siRNAs directly conjugated to N-acetyl galactosamine for hepatocyte delivery. ARO-HBV silences all mRNAs formed from covalently closed circular DNA (cccDNA) and host-integrated viral DNA. ARO-HBV is administered subcutaneously, so no absorption-related drug-drug interactions (DDI) occur.

JNJ-56136379 (JNJ-6379) is a Capsid Assembly Modulator (CAMs) being developed by Janssen Sciences. It works via a dual mechanism of action, formerly by interfering with capsid assembly and preventing covalently closed circular DNA (cccDNA) formation at de novo infection. It gets attached to the HBV core protein and obstructs both early and late-stage processes in the HBV life cycle. This drug in the monotherapy regimen is discontinued for further development due to the viral breakthrough observed in Phase II.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the JNJ-73763989 description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on JNJ-73763989 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JNJ-73763989 research and development activities in chronic hepatitis B across the United States and Europe.
• The report also covers the patents information with expiry timeline around JNJ-73763989.
• The report contains forecasted sales of JNJ-73763989 for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for JNJ-73763989 in chronic hepatitis B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JNJ-73763989 Analytical Perspective by DelveInsight

• In-depth JNJ-73763989 Market Assessment

This report provides a detailed market assessment of JNJ-73763989 for chronic hepatitis B in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2027 to 2032.

• JNJ-73763989 Clinical Assessment

The report provides the clinical trials information of JNJ-73763989 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JNJ-73763989 dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to JNJ-73763989 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JNJ-73763989 in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of JNJ-73763989 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JNJ-73763989 in chronic hepatitis B.

Key Questions:

• What is the product type, route of administration and mechanism of action of JNJ-73763989?
• What is the clinical trial status of the study related to JNJ-73763989 in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JNJ-73763989 development?
• What are the key designations that have been granted to JNJ-73763989 for chronic hepatitis B?
• What is the forecasted market scenario of JNJ-73763989 for chronic hepatitis B?
• What are the forecasted sales of JNJ-73763989 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain), and the United Kingdom?
• What are the other emerging products available and how are these giving competition to JNJ-73763989 for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

Table of Contents

1. Report Introduction

2. JNJ-73763989 Overview in Chronic hepatitis B

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. JNJ-73763989 Market Assessment

• 5.1. Market Outlook of JNJ-73763989 in Chronic hepatitis B
• 5.2. 6MM Analysis
  • 5.2.1. Market Size of JNJ-73763989 in the 6MM for Chronic hepatitis B
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of JNJ-73763989 in the United States for Chronic hepatitis B
  • 5.3.2. Market Size of JNJ-73763989 in Germany for Chronic hepatitis B
  • 5.3.3. Market Size of JNJ-73763989 in France for Chronic hepatitis B
  • 5.3.4. Market Size of JNJ-73763989 in Italy for Chronic hepatitis B
  • 5.3.5. Market Size of JNJ-73763989 in Spain for Chronic hepatitis B
  • 5.3.6. Market Size of JNJ-73763989 in the United Kingdom for Chronic hepatitis B

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options